Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555075 | 1.00 | LMNA (0.62) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1658859 | 0.92 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1658320 | 0.87 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL27818076 | 0.83 | ACE2 (0.41) | LMNABLMFDPS | |
| SCHEMBL29429107 | 0.81 | LMNA (0.56) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL20928 | 0.81 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8672325 | 0.81 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.81 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29662067 | 0.81 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL2381625 | 0.80 | TSHR (0.46) | LMNABLMPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041318-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | COMMUNITREAT LTD. (IL) | 2025-02-06 | — | — | US | disclosed |
| EP-4440698-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | Communitreat Ltd. (IL) | 2024-10-09 | — | — | EP | disclosed |
| CN-118742312-A | Sterilant compositions, kits and methods of use thereof | 柯姆尼治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023100184-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | COMMUNITREAT LTD. (IL) | 2023-06-08 | — | — | WO | disclosed |
| EP-3388088-B1 | AIR PURIFYING AGENT PREPARATION METHOD | WANG JINGNING (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-10314931-B2 | Air scavenger composition | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20190030200-A1 | AIR SCAVENGER COMPOSITION | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2019-01-31 | — | — | US | disclosed |
| EP-3388088-A1 | AIR PURIFYING AGENT COMPOSITION | Wang, Jingning (CN) | 2018-10-17 | — | — | EP | disclosed |
| CN-103998600-A | Functionalized carboxylic acids and alcohols by reverse fatty acid oxidation | UNIV RICE WILLIAM M | 2014-08-20 | — | — | CN | disclosed |
| CN-103370335-A | Novel biomarkers for liver cancer | MODPRO AB | 2013-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041318-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | NASP, ACR, ALPG | LMNA 1533/4885BLM 570/4885PTPN1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.